Reuters logo
BRIEF-Abivax says first patient dosed in phase 2a ABX464 study
September 18, 2017 / 6:22 AM / 3 months ago

BRIEF-Abivax says first patient dosed in phase 2a ABX464 study

Sept 18 (Reuters) - ABIVAX SA:

* ABIVAX: FIRST PATIENT DOSED IN THREE-MONTH COHORT OF PHASE 2A STUDY OF ORAL ABX464 IN HIV-SUPPRESSED PATIENTS

* INITIAL RESULTS OF FIRST COHORT ARE EXPECTED IN FIRST WEEK OF OCTOBER

* INITIAL RESULTS OF SECOND COHORT ARE EXPECTED IN Q2 OF 2018. Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below